Trulieve Cannabis (NYSE:TRLV) Given “Overweight” Rating at Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Trulieve Cannabis (NYSE:TRLV) in a report released on Friday,Benzinga reports. The brokerage currently has a $15.00 price target on the stock.

Several other equities research analysts have also recently weighed in on the stock. Zacks Research upgraded shares of Trulieve Cannabis to a “hold” rating in a research note on Thursday, June 18th. Wall Street Zen downgraded Trulieve Cannabis from a “strong-buy” rating to a “buy” rating in a research report on Sunday, July 12th. Finally, Weiss Ratings started coverage on Trulieve Cannabis in a report on Tuesday, June 16th. They set a “sell (d-)” rating on the stock. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $15.00.

Trulieve Cannabis Stock Down 2.7%

Shares of TRLV stock opened at $8.76 on Friday. Trulieve Cannabis has a 1 year low of $4.62 and a 1 year high of $13.28.

Trulieve Cannabis (NYSE:TRLV) last issued its quarterly earnings results on Friday, August 7th. The company reported $0.11 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.05. On average, sell-side analysts forecast that Trulieve Cannabis will post 0.2 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Kim A. Rivers sold 400,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $8.17, for a total transaction of $3,268,000.00. Following the completion of the transaction, the chief executive officer owned 1,913,724 shares in the company, valued at $15,635,125.08. This trade represents a 17.29% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 1,699,007 shares of company stock valued at $14,661,355. Corporate insiders own 3.79% of the company’s stock.

More Trulieve Cannabis News

Here are the key news stories impacting Trulieve Cannabis this week:

• Positive Sentiment: Trulieve reported second-quarter revenue of $271 million and a 60% gross margin. The company also generated $109 million in operating cash flow and $74 million in first-half free cash flow, highlighting improving profitability and liquidity. Trulieve Reports Second Quarter 2026 Results
• Positive Sentiment: Second-quarter EPS was $0.11, exceeding the $0.06 analyst consensus by $0.05. The earnings beat may support the bullish case for the stock. Trulieve Earnings Results
• Positive Sentiment: Cantor Fitzgerald reaffirmed its “overweight” rating and set a $15 price target, implying substantial upside from recent trading levels. Cantor Fitzgerald Rating
• Neutral Sentiment: Recent coverage focuses on key operational and market signals investors should monitor following the earnings release, but it does not identify a major new catalyst. Trulieve Key Signals to Watch
• Negative Sentiment: Wall Street Zen lowered Trulieve’s rating to “Hold,” signaling more cautious expectations and potentially offsetting the positive earnings surprise. Trulieve Rating Lowered to Hold

Trulieve Cannabis Company Profile

Trulieve Cannabis Corp. is a vertically integrated cannabis company focused on the cultivation, processing, and retail sale of medical and adult-use cannabis products. The company offers a range of products that may include flower, pre-rolls, concentrates, edibles, vape products, and topicals through its dispensary network and branded product portfolio.

Trulieve’s operations have been centered primarily in the United States, with a strong presence in Florida and additional markets in other states where cannabis is legally regulated.